- Investor's Business Daily•42 minutes ago
Wall Street will be eyeing Cosentyx sales when Novartis reports its first-quarter earnings Tuesday.
- Market Realist•7 hours ago
As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a "buy."
- Zacks•11 hours ago
As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.
NOT.SG : Summary for NOVARTIS AG NAMENS-AKTIEN SF 0, - Yahoo Finance